OCULAR THERAPEUTIX, INC Net Fee Amt
OCULAR THERAPEUTIX, INC (OCUL) had Net Fee Amt of $11.60 thousand as of 2026-07-30, per its S-8 filed 2026-08-03.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-08-03
- 2026-07-30: Net Fee Amt $11.60K.
| Period end | Net Fee Amt |
|---|---|
| 2026-07-30 | $11.60K S-8 · filed 2026-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |